Investigator Initiated Studies

Safety of biologic disease modifiers in rheumatoid arthritis in a clinical setting as a function of their responsiveness and correlation with clinical outcomes biomarkers in RA.

This study examines the safety and efficacy of standard treatments for Rheumatoid Arthritis in a clinical setting rather than a trial setting.  In other words, using the Rheumatology Health Tracking system, we are studying the effects therapies have the way that they are prescribed in the "real world".

PI: Jeffrey Lisse, MD

Agency:  Centocor, Inc.